ValuEngine lowered shares of Beigene (NASDAQ:BGNE) from a hold rating to a sell rating in a research note issued to investors on Wednesday morning.

Other analysts have also issued reports about the company. Maxim Group set a $120.00 price objective on Beigene and gave the company a buy rating in a report on Monday, December 18th. Robert W. Baird reissued a neutral rating and issued a $83.00 price objective (up from $58.00) on shares of Beigene in a report on Tuesday, November 14th. Cowen reissued a buy rating on shares of Beigene in a report on Tuesday, November 14th. Morgan Stanley reissued an overweight rating and issued a $95.00 price objective (up from $87.00) on shares of Beigene in a report on Friday, October 6th. Finally, Zacks Investment Research lowered Beigene from a hold rating to a sell rating in a report on Monday, November 13th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Beigene presently has a consensus rating of Buy and an average price target of $96.67.

Shares of Beigene (NASDAQ BGNE) opened at $98.52 on Wednesday. The company has a quick ratio of 9.27, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. Beigene has a fifty-two week low of $30.02 and a fifty-two week high of $118.95.

Beigene (NASDAQ:BGNE) last announced its quarterly earnings data on Monday, November 13th. The company reported $2.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $2.31. The firm had revenue of $220.21 million during the quarter, compared to the consensus estimate of $1.55 million. During the same period in the prior year, the firm earned ($1.08) earnings per share. research analysts anticipate that Beigene will post -2.04 EPS for the current fiscal year.

In other news, CEO John Oyler sold 150,957 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $80.50, for a total transaction of $12,152,038.50. Following the completion of the transaction, the chief executive officer now directly owns 491,891 shares of the company’s stock, valued at $39,597,225.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CMO Jane Huang sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $98.00, for a total value of $98,000.00. Following the transaction, the chief marketing officer now directly owns 1,000 shares of the company’s stock, valued at $98,000. The disclosure for this sale can be found here. Insiders have sold 483,482 shares of company stock valued at $42,139,474 over the last ninety days. Corporate insiders own 19.90% of the company’s stock.

Several large investors have recently bought and sold shares of BGNE. SG Americas Securities LLC bought a new position in shares of Beigene during the second quarter valued at approximately $111,000. Quantbot Technologies LP bought a new position in shares of Beigene during the third quarter valued at approximately $160,000. Profund Advisors LLC bought a new position in shares of Beigene during the second quarter valued at approximately $248,000. Teachers Retirement System of The State of Kentucky bought a new position in shares of Beigene during the third quarter valued at approximately $248,000. Finally, Aperio Group LLC bought a new position in shares of Beigene during the third quarter valued at approximately $301,000. 55.32% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Beigene (BGNE) Cut to “Sell” at ValuEngine” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/beigene-bgne-cut-to-sell-at-valuengine/1797216.html.

Beigene Company Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with Analyst Ratings Network's FREE daily email newsletter.